Article

MRI Can Predict Progression to Multiple Sclerosis from Clinically Isolated Syndrome

Author(s):

Certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis within the first year following diagnosis of clinically isolated syndrome.

This article originally appeared on The American Journal of Managed Care.

A study recently published in

Brain and Behavior

has shown that certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis (MS) within the first year following diagnosis of clinically isolated syndrome (CIS).

CIS is a precursor to MS in many patients eventually diagnosed with the disease. However, the uncertainty of progression following the first episode of CIS, with some patients not progressing to MS until many years later, hinders decision making on the optimal time for treatment initiation in these patients. Being unable to differentiate between patients who are at higher risk of progression to MS within 1 year versus those at lower risk puts a greater strain on physicians, who have to decide whether patients require treatment shortly after their initial CIS episode.

Results from previous studies, which sought to identify key MRI and patient parameters that would predict long-term outcomes for patients after their first CIS attack, served as a baseline. However, these studies failed to analyze patient conversion to MS within the first year following CIS. The current research seeks to address this question and to help identify specific MRI parameters that correlate with progression within the first year of CIS.

Of the 46 patients who were analyzed for disease recurrence, 21 had no recurrence within the first year while 25 had another clinical episode. Lesion location, number of lesions, and lesion length were notably different between the 2 outcomes. For lesion location, the temporal lobe, occipital lobe, and the area perpendicular to the corpus callosum were significantly more involved among the 25 patients who progressed to MS. The number of lesions and lesion length were also both greater in patients who progressed compared to those who did not.

Upon further inspection of the results, researchers determined that patients with greater than 13 lesions, lesion length greater than 0.75 cm, and the presence of lesions perpendicular to the corpus callosum had a 19 times greater risk of developing a second episode.

Continue reading here.

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Alzheimer and dementia clock drawing cognitive test -- Image credit: Jovana Milanko/Stocksy | stock.adobe.com
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Caregiver holding elderly man's hand -- Image credit: Chinnapong | stock.adobe.com
Health care worker looking at MRI scans of dementia -- Image credit: Atthapon | stock.adobe.com